Results 151 to 160 of about 86,629 (276)

Faculty Opinions recommendation of Dysregulation of sphingolipid metabolism contributes to bortezomib-induced neuropathic pain.

, 2020
Paul Farquhar-Smith, Richard Gordon-Williams   +1 more
openalex   +2 more sources

Complete and Partial Responses of the TEMPI Syndrome to Bortezomib [PDF]

, 2012
Wilfried Schroyens, Casey L. O’Connell, David B. Sykes   +2 more
openalex   +1 more source

Upregulation of Protein Synthesis and Proteasome Degradation Confers Sensitivity to Proteasome Inhibitor Bortezomib in Myc-Atypical Teratoid/Rhabdoid Tumors [PDF]

, 2020
Huy Tran, Kuo-Sheng Wu, Shian‐Ying Sung, Chun A. Changou, Tsung‐Han Hsieh, Yun-Ru Liu, Yen‐Lin Liu, Min‐Lan Tsai, Hsin‐Lun Lee, Kevin Li‐Chun Hsieh, Wen-Chang Huang, Muh‐Lii Liang, Hsin‐Hung Chen, Yi‐Yen Lee, Shih‐Chieh Lin, Donald Ming-Tak Ho, Feng-Chi Chang, Meng-En Chao, Wan Chen, Shing-Shung Chu, Alice L. Yu, Yun Yen, Che‐Chang Chang, Tai‐Tong Wong   +23 more
openalex   +1 more source

DNA methyltransferase inhibitors in hematological malignancies and solid tumors

International Journal of Cancer, Volume 158, Issue 2, Page 433-461, 15 January 2026.
Abstract Epigenetic modifications such as DNA methylation play a fundamental role in oncogenesis and the progression of neoplasms neoplasias. DNA methyltransferase inhibitors (DNMTi) constitute a family of therapeutic agents that impede the methylation at the 5‐position on cytosine nucleotides, thereby modulating the epigenetic regulation of tumor ...
Valentin Wenger, Guillermo Garcia‐Manero, Robert Zeiser, Michael Lübbert   +3 more
wiley   +1 more source

Non‐Secretory Myeloma With Non‐Producing Phenotype Presented as Plasma Cell Leukaemia With Plasmablast Morphology

eJHaem, Volume 7, Issue 1, February 2026.
Ke Xu, Ian Proctor
wiley   +1 more source

High levels of tRNA abundance and alteration of tRNA charging by bortezomib in multiple myeloma

, 2009
Ying Zhou, Jeffrey M. Goodenbour, Lucy A. Godley, Amittha Wickrema, Tao Pan   +4 more
openalex   +1 more source

Bortezomib in patients with renal impairment [PDF]

, 2011
Işık Kaygusuz, Tayfur Toptaş, Fergun Aydin, Ant Uzay, Tülin Firatli‐Tuglular, Mahmut Bayık   +5 more
openalex   +1 more source

Cyclophosphamide, Bortezomib, and Dexamethasone and Severe Systolic Heart Failure: A Case Report [PDF]

Sagar Pandey, Ernestine Faye S Tan, Amulya Bellamkonda, Binit Aryal, Madhumati Kalavar   +4 more
openalex   +1 more source

Bortezomib suppresses self‐renewal and leukemogenesis of leukemia stem cell by NF‐ĸB‐dependent inhibition of CDK6 in MLL‐rearranged myeloid leukemia [PDF]

, 2021
Bin Zhou, Yaqian Qin, Jingying Zhou, Jichen Ruan, Fang Xiong, Jinglai Dong, Xingzhou Huang, Zhijie Yu, Shenmeng Gao   +8 more
openalex   +1 more source

A Phase 2 study of bortezomib combined with either idarubicin/cytarabine or cytarabine/etoposide in children with relapsed, refractory or secondary acute myeloid leukemia: A report from the Children's Oncology Group

, 2014
Terzah M. Horton, John P. Perentesis, Alan S. Gamis, Todd A. Alonzo, Robert B. Gerbing, Jennifer Ballard, Kathleen Adlard, Dianna S. Howard, Franklin O. Smith, Gaye Jenkins, Angèle Kelder, Gerrit Jan Schuurhuis, Jeffrey A. Moscow   +12 more
openalex   +1 more source